Results 111 to 120 of about 105,382 (285)

Factors contributing to non-reporting of medication errors

open access: yesGlobal Pediatrics
Introduction: Medication errors are the most common adverse drug events in hospitals, which are easily preventable. Therefore, reporting on their occurrence is one of the critical issues of the entire healthcare system.
Branislava Brestovački Svitlica   +1 more
doaj   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

open access: yesMolecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi   +7 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Study on effectiveness of Medication Error Reporting System in Hospital Batu Pahat [PDF]

open access: yes, 2009
Medication safety is one of the major components in patient safety but unfortunately medication errors do happen and often and go undetected. One of the mechanisms to identify and monitor this error is by implementing "Medication Error Reporting System ...
Khamis, Rosaniza   +3 more
core  

Survey of Nurses\' Viewpoints on Causes of Medicinal Errors and Barriers to Reporting in Pediatric Units in Hospitals of Mashhad University of Medical Sciences [PDF]

open access: yesJournal of Advanced Biomedical Sciences, 2012
Background and Objective: Patient safety is the principal concern of current health care delivery systems, and several recent studies initiated by the Institute of Medicine have reported a high incidence of medicinal errors. Of the approximately 44000-
Masoomeh Seidi, Roghih Zardosht
doaj   +2 more sources

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

open access: yesMolecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy   +10 more
wiley   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

open access: yesMolecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel   +12 more
wiley   +1 more source

Prevalence, Types of Medication errors and Barriers to Reporting Errors by Nurses in an Educational Hospital in Kermanshah

open access: yesحیات, 2013
Background & Aim: The most common types of medical errors are medication errors. Medication errors can cause serious health problems and should be considered a threat to patientschr('39') safety.
Maryam Mirzaei   +3 more
doaj  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy